Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Normal Healthy Eyes Clear all

Conditions: Alopecia, Breast Cancer
Interventions: bimatoprost ophthalmic solution, placebo; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteer, Sjogren's Syndrome, Salivary Gland Disease
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 4 Years to 100 Years
Enrollment: 1,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma, Visual Field Defect
Interventions: Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence; Device
Lead sponsor: Sight Intelligence Engineering Corporation; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Mydriasis, Dilation
Interventions: Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo); Drug · Other
Lead sponsor: Ocuphire Pharma, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 4
States / cities: Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more

Conditions: Cataract, Lens Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Sarcoidosis, Dental Caries, Sjorgren's Syndrome, Cystinosis, Head and Neck Neoplasms
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Normal Physiology, Healthy Volunteers, Pain
Interventions: Medoc thermal stimulator, Electric shock stimulator, Cold water bath, Pain assessment performance feedback; Device · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Heidelberg Engineering GmbH; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers, Sjögren's Syndrome
Interventions: ASP5502, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes, Eyes With Retinal Diseases
Interventions: 3D OCT-1 Maestro, iVue; Device
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Pomona, California

Conditions: Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes, Eyes With Retinal Diseases
Interventions: Maestro, iVue; Device
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Pomona, California • New York, New York

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Oakland, New Jersey

Conditions: Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Interventions: R89674 (generic name not yet established); Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 3 Years and older
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 6
States / cities: Phoenix, Arizona • Bel Air, Maryland • North Andover, Massachusetts + 3 more

Conditions: Healthy
Interventions: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P); Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy
Interventions: quick Contrast Sensitivity Function test; Other
Lead sponsor: Nova Southeastern University; Other
Eligibility: 20 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Pulmonary Fibrosis, Healthy Volunteers, Hermansky-Pudlak Syndrome (HPS)
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 115 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Allergic Conjunctivitis
Interventions: contact lens with ketotifen, contact lens; Device
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 8 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions: XmAb7195, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Normal Healthy Subjects With no Known Ocular Diseases
Interventions: Topcon TRC-NW400, TRC-NW8, TRC-NW400, Canon-CR2, Zeiss Visucam PRO; Device
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Oakland, New Jersey

Conditions: Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome, Parkinson's Disease
Interventions: Computer Tablet Group, Paper and Pencil Group, Contact Control Group; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 76 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Characterization of Diseases With Salivary Gland Involvement

Visual Field Analysis With Artificial Intelligence

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Magnetic Resonance Imaging to Study the Normal Eye

Salivary Proteins in Disease and Health

Sociocultural & Biobehavioral Influences on Pain Expression and Assessment

Optical Coherence Tomography (OCT) Normative Data Collection Study

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

Maestro Agreement and Precision Study II

Clinical Study of the Optic Disc Parameters

TopQ Cut-off Determination Study For 3D-OCT 1 Maestro and 3D OCT-2000

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Test-Retest Variability of Quick Contrast Sensitivity Function Testing

Analysis of Specimens From Individuals With Pulmonary Fibrosis

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Retinal Fundus Camera Evaluation

e-Mobile Tablet for People With Chronic Conditions